MAP2K4 and ovarian carcinoma: Despite this accumulating evidence, the status of MAP2K4 as a tumor suppressor in ovarian cancer is equivocal and therefore in this study we have undertaken a comprehensive analysis of mutation, methylation and gene knockdown.